KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Cash & Equivalents: 2009-2024

Historic Cash & Equivalents for Pacira BioSciences (PCRX) over the last 16 years, with Dec 2024 value amounting to $276.8 million.

  • Pacira BioSciences' Cash & Equivalents fell 40.00% to $147.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $147.6 million, marking a year-over-year decrease of 40.00%. This contributed to the annual value of $276.8 million for FY2024, which is 80.55% up from last year.
  • As of FY2024, Pacira BioSciences' Cash & Equivalents stood at $276.8 million, which was up 80.55% from $153.3 million recorded in FY2023.
  • Over the past 5 years, Pacira BioSciences' Cash & Equivalents peaked at $585.6 million during FY2021, and registered a low of $100.0 million during FY2020.
  • Over the past 3 years, Pacira BioSciences' median Cash & Equivalents value was $153.3 million (recorded in 2023), while the average stood at $178.1 million.
  • Per our database at Business Quant, Pacira BioSciences' Cash & Equivalents skyrocketed by 485.83% in 2021 and then plummeted by 82.22% in 2022.
  • Over the past 5 years, Pacira BioSciences' Cash & Equivalents (Yearly) stood at $100.0 million in 2020, then spiked by 485.83% to $585.6 million in 2021, then tumbled by 82.22% to $104.1 million in 2022, then spiked by 47.21% to $153.3 million in 2023, then skyrocketed by 80.55% to $276.8 million in 2024.